Abstract
An isoenzyme of pyruvate kinase (Tu M2-PK) is overexpressed by tumor cells and can be measured in blood by a specific immunoenzymatic assay. Our objective was to investigate the diagnostic value of Tu M2-PK in comparison with that of CA 19-9 in pancreatic cancer. We studied 265 subjects: 60 with histologically confirmed pancreatic cancer, 43 with benign pancreatic diseases (acute and chronic pancreatitis), 5 with benign cystic neoplasms of the pancreas, 9 with neuroendocrine tumors, 77 with other abdominal malignancies, 47 with benign digestive diseases, and 24 healthy controls. Levels of plasma Tu M2-PK and serum CA 19-9 were determined by commercially available specific immunoassays. The diagnostic sensitivity and specificity of Tu M2-PK for pancreatic cancer were 85 and 41%, respectively, while those of CA 19-9 were 75 and 81%. The combination of the two tests significantly increased sensitivity (97%) but lowered specificity (38%). In discriminating between pancreatic cancer and acute or chronic pancreatitis, Tu M2-PK turned out to be less accurate than CA 19-9. In patients without pancreatic tumor, cholestasis appeared not to affect the values of Tu M2-PK, while CA 19-9 was found to be significantly higher. Tu M2-PK was also abnormally high in the majority of patients with other digestive malignancies or neuroendocrine tumors. The results demonstrate that Tu M2-PK has a satisfactory sensitivity but a poor specificity in the diagnosis of pancreatic cancer. Used together with CA 19-9, the sensitivity increases considerably.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Malesci A, Montorsi M, Mariani A, Santambrogio R, Bonato C, Bissi O, Tacconi M, Wizemann G, Spina G: Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas7:497–502, 1992
Gullo L: CA 19-9: the Italian experience. Pancreas9:717–719, 1994
Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A, Beretta E, Di Carlo V: Determination of CA 19-9antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology92:60–67, 1987
Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, Pugliese V: CA 19.9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer61:2100–2108, 1988
Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R: Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog3:91–115, 1992
Eigenbrodt E, Kallinowski F, Ott M, Mazurek S, Vaupel P:Pyruvate kinase and interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res18:3267–3274, 1998
Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G: Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 3153–3156, 1997
Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH: The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.Anticancer Res19:2599–2601, 1999
Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K: Tumor type M2 pyruvate kinase expression in advanced breast cancer.Anticancer Res20:5077–5082, 2000
Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E: Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev24:531–535, 2000
Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU: Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res20:4965–4968, 2000
Schulze G: The tumor marker tumor M2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res20:4961–4964,2000
Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, Mischinger HJ: TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res19:849–851, 1999
Oremek GM, Eigenbrodt E, Radle J, Zeuzem S, Seiffert UB: Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res17:3031–3034, 1997
UICC TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 3rd ed.Berlin, Eidelberg, New York, Springer-Verlag,1989
Hugo F, Fischer G, Eigenbrodt E: Quantitative detection of tumor M2-PK in serum and plasma.Anticancer Res19:2753–2757, 1999
National Cancer Institute: Annual Report to the Nation on the Status of Cancer, 1973-1998. The Surveillance, Epidemiology, and End Results (SEER). NCI, Bethesda, MD.
Rhodes JM, Yannakou Y, Ching CK: Pancreatic tumor markers. InThe Pancreas HJ Beger (ed). Oxford, Blackwell Science, 1998, pp 966–981
Wechsel HW, Petri E, Bichler KH, Feil G: Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res19:2583–2590, 1999
Oehler R, Weingartmann G, Manhart N, Salzer U, Meissner M, Schlegel W, Spittler A, Bergmann M, Kandioler D, Oismuller C, Struse HM, Roth E: Polytrauma induces increased expression of pyruvate kinase in neutrophils. Blood 95:1086–1092, 2000
Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, Corinaldesi R: Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Anticancer Res23:2969–2972, 2003
Goldstein SA, Elwyn DH: The effects of injury and sepsis on fuel utilization.Annu Rev Nutr9:445–473, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ventrucci, M., Cipolla, A., Racchini, C. et al. Tumor M2-Pyruvate Kinase, a New Metabolic Marker for Pancreatic Cancer. Dig Dis Sci 49, 1149–1155 (2004). https://doi.org/10.1023/B:DDAS.0000037803.32013.aa
Issue Date:
DOI: https://doi.org/10.1023/B:DDAS.0000037803.32013.aa